HomeAI · summaries
Storia in 4 fonti
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease…
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
- ·
healio.com
FDA expands Casgevy approval to children 2 years and older with sickle cell disease
The FDA has approved a label expansion for Casgevy to include patients aged 2 years and older with sickle cell disease and transfusion-dependent beta thalassemia. Previously…
- ·
medpagetoday.com
FDA Approves Sickle Cell Gene Therapy for Young Kids
Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years and up
- ·
endpoints.news
Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
Vertex's Casgevy wins pediatric approval, United Therapeutics buys Thymmune for up to $300M, plus deals from Insilico, Fosun and Abbisko.